Ionis posts CORE-TIMI severe hypertriglyceridemia olezarsen data presentation

Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

IONS

0.00
  • Ionis published a CORE/CORE2 slide deck on olezarsen in severe hypertriglyceridemia, highlighting triglyceride reductions across 50 mg and 80 mg doses.
  • Pooled analysis showed acute pancreatitis risk reduction with RR 0.15 (0.05-0.40), absolute risk reduction 5.2%, NNT 20 over 1 year.
  • High-risk subgroup (TGs ≥880 mg/dL with prior pancreatitis) showed RR 0.17 (0.06-0.47), absolute risk reduction 32.5%, NNT 4.
  • Safety summary flagged higher injection-site reactions, more ALT/AST ≥3x ULN at 80 mg (7%), platelet count <100K/uL at 80 mg (7%).


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief on June 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.